专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011094579A3 MUSHROOM COMPOSITIONS AND METHODS FOR MAKING AND USING 审中-公开
标题翻译： MUSHROOM组合物和制备和使用的方法
公开(公告)号：WO2011094579A3
公开(公告)日：2011-09-29
申请号：PCT/US2011022976
申请日：2011-01-28
申请人： NEW CHAPTER INC , UNIV TEXAS , YANG PEIYING , NEWMAN ROBERT A , SCHULICK PAUL
发明人： YANG PEIYING , NEWMAN ROBERT A , SCHULICK PAUL
IPC分类号： A61K36/07
CPC分类号： A61K36/074 , A61K36/068 , A61K36/07 , A61K36/076 , A61K2300/00
摘要： The present subject matter relates to a novel mushroom composition and methods for making and using the same. In one aspect, the subject matter involves a composition comprising a combination of mushrooms or components derived from mushrooms selected from the group consisting of Reishi Ganoderma lucidum, Reishi Ganoderma lucidum, Cordyceps sinensis, Maitake Grifola frondosa, Shiitake Lentinula edodes, Poria cocos, Lion's Mane Hericium erinaceus, Mesima Phellinus linteus, Turkey Tail Coriolus Tramentes versicolor, Chaga Inonotus obliquus, and Chaga Inonotus obliquus. In some embodiments, the present subject matter relates to methods for modulating immune function, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders. In one embodiment the composition provides a balancing of anti-inflammatory and pro-inflammatory function in an animal, including in humans.
摘要翻译：本发明涉及一种新颖的蘑菇组合物及其制备和使用方法。在一个方面，主题涉及一种组合物，其包含蘑菇或来自蘑菇的组分的组合，所述蘑菇或选自以下的蘑菇：灵芝灵芝，灵芝灵芝，冬虫夏草，山茱萸，叶螨，茯苓，狮子鬃 Hericium erinaceus，Mesima Phellinus linteus，Turkey Tail Coriolus Tramentes versicolor，Chaga Inonotus obliquus和Chaga Inonotus obliquus。在一些实施方案中，本主题涉及调节免疫功能，调节脂氧合酶和环加氧酶的活性，改善心血管健康和/或抑制细胞增殖疾病和病症的方法。在一个实施方案中，所述组合物在动物（包括人）中提供抗炎和促炎功能的平衡。

2. 发明申请

WO2011085307A1 METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH CARDIAC GLYCOSIDES 审中-公开
标题翻译：用心脏糖尿病治疗神经病症的方法
公开(公告)号：WO2011085307A1
公开(公告)日：2011-07-14
申请号：PCT/US2011/020672
申请日：2011-01-10
申请人： PHOENIX BIOTECHNOLOGY, INC. , ADDINGTON, Otis, C. , NEWMAN, Robert, A.
发明人： ADDINGTON, Otis, C. , NEWMAN, Robert, A.
IPC分类号： A01N45/00
CPC分类号： A61K31/704 , A61K31/7048 , A61K36/24 , A61K45/06 , G01N33/5088 , G01N2800/2821 , G01N2800/2835 , G01N2800/2871 , G01N2800/52
摘要： A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.
摘要翻译：提供了通过施用强心苷治疗受试者的神经病症的方法。通过向受试者施用治疗有效量的心脏糖苷来治疗阿尔茨海默氏病，亨廷顿舞蹈病或中风。强心苷可以以剂型存在。

3. 发明申请

WO2008144706A2 SWEET GUM FRUIT EXTRACT AS A THERAPEUTIC AGENT 审中-公开
标题翻译：作为治疗剂的甜菜糖果提取物
公开(公告)号：WO2008144706A2
公开(公告)日：2008-11-27
申请号：PCT/US2008/064303
申请日：2008-05-21
申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE , BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , LIU, Zhijun , YANG, Peiying , NEWMAN, Robert, A.
发明人： LIU, Zhijun , YANG, Peiying , NEWMAN, Robert, A.
IPC分类号： A61K36/20
CPC分类号： A61K36/185 , A61K45/06
摘要： Sweet gum ( Liquidambar styraciflua L., family Hamamelidaceae) fruit extract was discovered to possess potent activities against multiple targets of the PBK (phosphatidylinositide 3-kinase) pathway, especially the PI3K/Akt and mTOR pathways. At a very low concentration of 1.85 μg/ml (IC50), sweet gun extract showed the ability of simultaneously blocking the pathways of PI3K/Akt (upstream), mTOR (mammalian target of rapamycin) (downstream), as well as its downstream protein products S6K and S6. It was also able to block 5-HETE, a lipoxygenase product that contributes to inflammation and activation of PI3K/Akt. The sweet gum fruit extract was prepared with 50% methanol (47: 1; raw to extract) and concentrated to an organic fraction (210: 1 raw to extract) referred as LIS-100 via reverse-phase column chromatography using a bioassay directed fractionation approach. The extract is a new targeted therapeutic agent for numerous disorders known to be treated by mTOR inhibitors, including cancer, diabetes, obesity, and inflammation.
摘要翻译：发现甜口香糖（枫香香a，，家amel科）水果提取物具有针对PBK（磷脂酰肌醇3-激酶）途径的多个靶点，特别是PI3K / Akt和mTOR途径的有效活性。在1.85μg/ ml（IC 50）的非常低的浓度下，甜枪提取物显示同时阻断PI3K / Akt（上游），mTOR（雷帕霉素的哺乳动物靶标）（下游）以及其下游蛋白质的途径的能力产品S6K和S6。它还能够阻断5-HETE，一种有助于PI3K / Akt的炎症和活化的脂氧合酶产物。用50％甲醇（47:1，未加萃取物）制备甜口香糖果提取物，并通过反相柱色谱法使用生物测定方向分馏法浓缩成称为LIS-100的有机级分（210:1原始提取物）做法。提取物是已知用mTOR抑制剂治疗的许多病症的新靶向治疗剂，包括癌症，糖尿病，肥胖症和炎症。

4. 发明申请

WO2004092430A2 COMPOSITION FOR MAKING METAL MATRIX COMPOSITES 审中-公开
标题翻译：用于制备金属基复合材料的组合物
公开(公告)号：WO2004092430A2
公开(公告)日：2004-10-28
申请号：PCT/US2004010837
申请日：2004-04-08
申请人： DOW GLOBAL TECHNOLOGIES INC , PYZIK ALEKSANDER J , HU TERRY I , MORGAN TED A , LISTER DANIEL R , NEWMAN ROBERT A , LUNGARD RICHARD ALLEN , DENG QIN
发明人： PYZIK ALEKSANDER J , HU TERRY I , MORGAN TED A , LISTER DANIEL R , NEWMAN ROBERT A , LUNGARD RICHARD ALLEN , DENG QIN
IPC分类号： C22C1/10 , C23C14/06 , C23C14/22 , C22C1/00
CPC分类号： C23C14/223 , C04B35/62857 , C04B35/6286 , C04B35/62865 , C04B35/62873 , C04B35/62876 , C04B35/62884 , C04B35/62894 , C04B2235/3217 , C04B2235/3418 , C04B2235/3804 , C22C1/101 , C22C1/1036 , C22C47/04 , C22C47/06 , C22C2001/1021 , C23C14/0641 , C23C14/067 , Y10T428/12007 , Y10T428/31678
摘要： In one embodiment, a composition (10) to be mixed with a molten metal to make a metal matrix composite, the composition characterized by: a ceramic reinforcing filler (12), the ceramic reinforcing filler not being wettable by molten aluminum and/or not being chemically stable in molten aluminum, the ceramic reinforcing filler being coated with a ceramic material, the ceramic material being wettable by and chemically stable in molten aluminum. In a related embodiment, a composition (20) to make a porous preform to be infiltrated by molten metal to make a metal matrix composite, the composition characterized by: a ceramic reinforcing filler (23), the ceramic reinforcing filler not being wettable by molten aluminum, the ceramic reinforcing filler being coated with a ceramic material (22) and optionally with a metal (21) such as nickel, the ceramic material being wettable by molten aluminum. The ceramic material can be coated on the ceramic reinforcing filler by a vacuum deposition technique such as vacuum sputtering.
摘要翻译：在一个实施方案中，与熔融金属混合以制备金属基质复合材料的组合物（10），所述组合物的特征在于：陶瓷增强填料（12），所述陶瓷增强填料不能被熔融铝和/或不熔化在熔融铝中化学稳定，陶瓷增强填料用陶瓷材料涂覆，陶瓷材料可在熔融铝中润湿并化学稳定。在相关实施例中，一种组合物（20），用于使多孔预成型体浸入熔融金属中以制成金属基质复合物，该组合物的特征在于：陶瓷增强填料（23），陶瓷增强填料不能被熔融铝，陶瓷增强填料涂覆有陶瓷材料（22）和任选地与金属（21）如镍，陶瓷材料可被熔融的铝润湿。陶瓷材料可以通过真空沉积技术如真空溅射涂覆在陶瓷增强填料上。

5. 发明申请

WO2008144706A3 SWEET GUM FRUIT EXTRACT AS A THERAPEUTIC AGENT 审中-公开
标题翻译：作为治疗剂的甜菜糖果提取物
公开(公告)号：WO2008144706A3
公开(公告)日：2009-01-15
申请号：PCT/US2008064303
申请日：2008-05-21
申请人： UNIV LOUISIANA STATE , UNIV TEXAS , LIU ZHIJUN , YANG PEIYING , NEWMAN ROBERT A
发明人： LIU ZHIJUN , YANG PEIYING , NEWMAN ROBERT A
IPC分类号： A61K36/20
CPC分类号： A61K36/185 , A61K45/06
摘要： Sweet gum (Liquidambar styraciflua L., family Hamamelidaceae) fruit extract was discovered to possess potent activities against multiple targets of the PBK (phosphatidylinositide 3-kinase) pathway, especially the PI3K/Akt and mTOR pathways. At a very low concentration of 1.85 µg/ml (IC50), sweet gun extract showed the ability of simultaneously blocking the pathways of PI3K/Akt (upstream), mTOR (mammalian target of rapamycin) (downstream), as well as its downstream protein products S6K and S6. It was also able to block 5-HETE, a lipoxygenase product that contributes to inflammation and activation of PI3K/Akt. The sweet gum fruit extract was prepared with 50% methanol (47: 1; raw to extract) and concentrated to an organic fraction (210: 1 raw to extract) referred as LIS-100 via reverse-phase column chromatography using a bioassay directed fractionation approach. The extract is a new targeted therapeutic agent for numerous disorders known to be treated by mTOR inhibitors, including cancer, diabetes, obesity, and inflammation.
摘要翻译：发现甜口香糖（枫香香a，，家amel科）水果提取物具有针对PBK（磷脂酰肌醇3-激酶）途径的多个靶点，特别是PI3K / Akt和mTOR途径的有效活性。在1.85μg/ ml（IC 50）的非常低的浓度下，甜枪提取物显示同时阻断PI3K / Akt（上游），mTOR（雷帕霉素的哺乳动物靶标）（下游）以及其下游蛋白的途径的能力产品S6K和S6。它还能够阻断5-HETE，一种有助于PI3K / Akt的炎症和活化的脂氧合酶产物。用50％甲醇（47:1，未加萃取物）制备甜口香糖果提取物，并通过反相柱色谱法使用生物测定方向分馏法浓缩成称为LIS-100的有机级分（210:1原始提取物）做法。提取物是已知用mTOR抑制剂治疗的许多病症的新靶向治疗剂，包括癌症，糖尿病，肥胖症和炎症。

6. 发明申请

WO2012071152A4 METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH EXTRACT OF NERIUM SPECIES OR THEVETIA SPECIES 审中-公开
公开(公告)号：WO2012071152A4
公开(公告)日：2012-08-16
申请号：PCT/US2011059090
申请日：2011-11-03
申请人： PHOENIX BIOTECHNOLOGY INC , ADDINGTON OTIS C , NEWMAN ROBERT A
发明人： ADDINGTON OTIS C , NEWMAN ROBERT A
IPC分类号： A01N65/00
CPC分类号： A61K31/704 , A61K31/7048 , A61K36/24 , A61K45/06 , A61K2300/00
摘要： A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of Nerium species or Thevetia species is provided, wherein the extract, or fraction or sub-fraction thereof, excludes oleandrin and neriifolin. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of the extract, or a fraction or sub- fraction thereof, to a subject. The extract can be present in a pharmaceutical composition.

7. 发明申请

WO2012071152A3 METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH EXTRACT OF NERIUM SPECIES OR THEVETIA SPECIES 审中-公开
标题翻译：用N或THE种提取物治疗神经病症的方法
公开(公告)号：WO2012071152A3
公开(公告)日：2012-06-21
申请号：PCT/US2011059090
申请日：2011-11-03
申请人： PHOENIX BIOTECHNOLOGY INC , ADDINGTON OTIS C , NEWMAN ROBERT A
发明人： ADDINGTON OTIS C , NEWMAN ROBERT A
IPC分类号： A01N65/00
CPC分类号： A61K31/704 , A61K31/7048 , A61K36/24 , A61K45/06 , A61K2300/00
摘要： A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of Nerium species or Thevetia species is provided, wherein the extract, or fraction or sub-fraction thereof, excludes oleandrin and neriifolin. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of the extract, or a fraction or sub- fraction thereof, to a subject. The extract can be present in a pharmaceutical composition.
摘要翻译：提供了通过施用Nerium物种或Thevetia物种的提取物或其部分或子部分来治疗受试者中的神经病症的方法，其中提取物或其部分或子部分不包括夹竹桃苷和奈瑞芬林。阿尔茨海默病，亨廷顿舞蹈病或中风通过向受试者施用治疗有效量的提取物或其部分或亚部分来治疗。提取物可以存在于药物组合物中。

8. 发明申请

WO2011094579A2 MUSHROOM COMPOSITIONS AND METHODS FOR MAKING AND USING 审中-公开
标题翻译：蘑菇组合物及其制备和使用方法
公开(公告)号：WO2011094579A2
公开(公告)日：2011-08-04
申请号：PCT/US2011/022976
申请日：2011-01-28
申请人： NEW CHAPTER INC. , BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM , YANG, Peiying , NEWMAN, Robert, A. , SCHULICK, Paul
发明人： YANG, Peiying , NEWMAN, Robert, A. , SCHULICK, Paul
IPC分类号： A61K36/06 , A61P3/10 , A61P19/02 , A61P1/16 , A61P9/10 , A61P29/00 , A61P11/00 , A61P17/06 , A61P25/16
CPC分类号： A61K36/074 , A61K36/068 , A61K36/07 , A61K36/076 , A61K2300/00
摘要： The present subject matter relates to a novel mushroom composition and methods for making and using the same. In one aspect, the subject matter involves a composition comprising a combination of mushrooms or components derived from mushrooms selected from the group consisting of Reishi Ganoderma lucidum, Reishi Ganoderma lucidum, Cordyceps sinensis, Maitake Grifola frondosa, Shiitake Lentinula edodes, Poria cocos, Lion's Mane Hericium erinaceus, Mesima Phellinus linteus, Turkey Tail Coriolus Tramentes versicolor, Chaga Inonotus obliquus, and Chaga Inonotus obliquus. In some embodiments, the present subject matter relates to methods for modulating immune function, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders. In one embodiment the composition provides a balancing of anti-inflammatory and pro-inflammatory function in an animal, including in humans.
摘要翻译：本发明的主题涉及一种新型蘑菇组合物及其制备和使用方法。在一个方面，本主题涉及一种组合物，其包含蘑菇或衍生自蘑菇的组分的组合，所述组合选自由灵芝灵芝，灵芝灵芝，冬虫夏草，Maitake灰树花，香菇香菇，茯苓，狮子鬃猴头菌，Mesima Phellinus linteus，土耳其Tail Coriolus Tramentes versicolor，Chaga Inonotus obliquus和Chaga Inonotus obliquus。在一些实施方案中，本主题涉及用于调节免疫功能，调节脂氧合酶和环氧合酶的活性，改善心血管健康和/或抑制细胞增殖疾病和病症的方法。在一个实施方案中，组合物提供动物（包括人类）中的抗炎和促炎功能的平衡。

9. 发明申请

WO2010138902A1 COMPOSITIONS AND METHODS FOR MODULATING LIPID COMPOSITION 审中-公开
标题翻译：用于调节脂肪组合物的组合物和方法
公开(公告)号：WO2010138902A1
公开(公告)日：2010-12-02
申请号：PCT/US2010/036712
申请日：2010-05-28
申请人： NEW CHAPTER INC. , BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM , NEWMAN, Robert, A. , YANG, Peiying , SCHULICK, Paul
发明人： NEWMAN, Robert, A. , YANG, Peiying , SCHULICK, Paul
IPC分类号： A61K36/00
CPC分类号： A61K36/53 , A61K35/60 , A61K45/06
摘要： The present subject matter relates to a novel herbal and oil composition and methods for modulating fatty acid composition and metabolism in an animal. In one aspect, the subject matter involves a composition comprising rosemary extract, oregano extract, and a polyunsaturated oil. In a particular embodiment, the polyunsaturated oil is fish oil or a derivative thereof. In some embodiments, the present subject matter relates to methods for modulating essential dietary fatty acid composition of lipoprotein particles or cell membranes, modulating essential fatty acid metabolism, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and / or inhibiting cell proliferation diseases and disorders.
摘要翻译：本发明涉及用于调节动物脂肪酸组成和代谢的新颖的草药和油组合物和方法。在一个方面，主题涉及包含迷迭香提取物，牛至提取物和多不饱和油的组合物。在一个具体实施方案中，多不饱和油是鱼油或其衍生物。在一些实施方案中，本主题涉及调节脂蛋白颗粒或细胞膜的必需膳食脂肪酸组成，调节必需脂肪酸代谢，调节脂氧合酶和环加氧酶的活性，改善心血管健康和/或抑制细胞增殖疾病的方法和疾病。

10. 发明申请

WO2009064657A1 METHOD OF DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE 审中-公开
标题翻译：用CARDIAC GLYCOSIDE测定癌症化疗中治疗应答的可行性的方法
公开(公告)号：WO2009064657A1
公开(公告)日：2009-05-22
申请号：PCT/US2008/082641
申请日：2008-11-06
申请人： PHOENIX BIOTECHNOLOGY INC. , NEWMAN, Robert, A. , YANG, Peiying
发明人： NEWMAN, Robert, A. , YANG, Peiying
IPC分类号： A61K31/704 , A61K31/58 , G01N33/574
CPC分类号： G01N33/573 , A61K31/513 , A61K31/58 , A61K31/7008 , A61K31/704 , A61K31/7048 , A61K36/24 , A61K45/06 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , C12Y306/01003 , G01N33/574 , G01N33/6872 , G01N2333/914 , G01N2800/52 , G01N2800/7023 , G01N2800/7028 , G06F19/12
摘要： A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.
摘要翻译：提供预后测定法和试剂盒及其使用方法。该试剂盒和测定法用于确定具有与过量细胞增殖相关的病因的疾病中用强心苷治疗的治疗反应的患病细胞或组织的可能性。试剂盒和测定用于测定从患病细胞或组织获得的Na，K-ATP酶的a亚基的同种型的比例。该试剂盒可用于预测受试者用强心苷治疗的癌症或肿瘤的治疗反应性。试剂盒和测定法可以掺入一种用包含强心苷的组合物治疗与过量细胞增殖相关的病因的疾病或病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式